Mitokinin appoints Michael D. Taylor, PhD, Executive Chairman
October 1, 2019
Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for Parkinson’s disease, today announced the appointment of Michael D. Taylor, PhD, as Executive Chairman of the Company.
“We’re thrilled to welcome Mike to Mitokinin,” said Daniel de Roulet Jr, Mitokinin’s Chief Executive Officer. “It is a testament to the quality of our program that we were able to recruit someone of Mike’s caliber. His wealth of experience across both the discovery and clinical stages of therapeutic development will be invaluable to us as we chart our path forward.”
Dr. Taylor most recently served as Chief Executive Officer of Deciphera Therapeutics, where he successfully oversaw the clinical development of Ripretinib for GIST. Prior to Deciphera, he held a variety of management positions at Pfizer and Warner Lambert.
Mitokinin is late-preclinical stage biotechnology company developing PINK1-targeted therapeutics for Parkinson’s disease. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinson’s disease and ultimately slow or halt the progression of the disease. Learn more at www.mitokinin.com.